422 results about "Resistant organism" patented technology

The present invention relates to compositions comprising a combination of one or more antiseptic and an antibiotic. It is based, at least in part, on the discovery that such combinations tend to deter the formation of antibiotic-resistant organisms. In preferred, nonlimiting embodiments of the invention, the antibiotic is minocycline and the antiseptic is a chlorhexidine compound, triclosan, or benzalkonium chloride, and in particular embodiments, a silver salt or a bismuth salt is added. Examples of specific, nonlimiting embodiments of the invention include combinations of (i) minocycline, triclosan, and a bismuth salt; (ii) minocycline, a chlorhexidine compound, and a bismuth salt; and (iii) minocycline, benzalkonium chloride, and a bismuth salt. The present invention further provides for articles, such as, but not limited to, medical articles, which have been treated with or which otherwise comprise a combination of antiseptic and antibiotic.

The present invention relates to compositions comprising a combination of one or more antiseptic and an antibiotic. It is based, at least in part, on the discovery that such combinations tend to deter the formation of antibiotic-resistant organisms. In preferred, nonlimiting embodiments of the invention, the antibiotic is minocycline and the antiseptic is a chlorhexidine compound, triclosan, or benzalkonium chloride, and in particular embodiments, a silver salt or a bismuth salt is added. Examples of specific, nonlimiting embodiments of the invention include combinations of (i) minocycline, triclosan, and a bismuth salt; (ii) minocycline, a chlorhexidine compound, and a bismuth salt; and (iii) minocycline, benzalkonium chloride, and a bismuth salt. The present invention further provides for articles, such as, but not limited to, medical articles, which have been treated with or which otherwise comprise a combination of antiseptic and antibiotic.

The invention discloses a pleuromutilin derivate, a preparation method and medical use thereof. The pleuromutilin derivate is a compound, which is obtained by coupling pleuromutilin to alkyl acylamino-thiazole-4-methyl merecaptan with 2-different substitutional amino. Pharmacological experimental results show that: compared with the pleuromutilin, the pleuromutilin derivate disclosed by the invention has better antimicrobial and antibiotic resistant bacteria activities; and therefore, the compound is possibly applicable for curing a plurality of infection and inflammatory diseases on clinic.

Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and its drug resistant bacteria. Provided is a hydroxamic acid derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof:

The present invention relates to molecular immunology technology, and aims at screening out antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, researching protective immunoreaction mechanism against tuberculosis, and further developing new type of concatenate polyepitope tuberculosis vaccine. The present invention provides one kind of antigen epitope molecular simulation peptide capable of exciting human body's protective immunoreaction against tubercle bacillus, and the peptide contains the amino acid sequence selected from SEQ ID Nos. 2, 5, 10, 12, 14 and 15. The present invention also provides the screening process and use of the peptide. The present invention may be used in preventing and controlling tuberculosis.

The invention belongs to the technical field of medicines and particularly relates to a new function of micromolecular metabolin, namely glutamine. The micromolecule can improve the sensitivity of bacteria including drug-resistant bacteria to antibiotics so as to solve the problem of drug resistance of bacteria. The micromolecule provided by the invention has better effect and higher safety and operability compared with antibiotic which is applied to the medicament for resisting drug resistance of bacteria at present.

The invention belongs to the field of biological medicines, and discloses a novel use of a small molecule compound alanine. The research shows that the alanine is capable of enhancing the effect of the antibiotic to kill pathogenic bacteria including drug-resistance bacteria. The small molecule metabolite alanine provided by the invention can be used as a medicine for improving the sterilizing function of the antibiotic.

The invention belongs to the technical field of disinfectants, and discloses a leave-on skin care and disinfection gel containing a composite sterilization component. The leave-on skin care and disinfection gel is prepared through the following steps: immersing a humectant in deionized water 2 days ahead to dissolve the humectant; stirring and dissolving a thickener in water 1 day ahead; and taking an antibacterial agent at normal temperature, dissolving the antibacterial agent in ethanol, adding a quaternary ammonium salt disinfectant and a biguanide disinfectant, adding the above obtained completely dissolved thickener solution and the obtained dissolved humectant solution, stirring until uniformity, adjusting the pH value to 5.0-7.5 by using a neutralizer, adding deionized water to a full dose, stirring until uniformity, and solidifying. The disinfection gel enlarges the antibacterial spectrum range, is in favor of preventing generation of drug resistant bacteria, has the characteristics of no irritation, quick action and long action, overcomes disadvantages of sing composition disinfectants, and also has a skin care effect.

The invention discloses a carbapenem antibiotic resistant bacterium fluorescent probe. In a structural formula as shown in the specification, X refers to carbon atoms or sulfur atoms; when X is CH, R1 is methyl and can be R or S configuration, or X is CH2 or S; a dye is any one of boron-dipyrromethene, naphthalimides, coumarin, fluorescein or rhodamine. A synthesis method of the fluorescent probe includes steps: (1) preparation of a compound 3; (2) preparation of a compound 4; (3) preparation of a fluorescent probe CVB-1. The fluorescent probe can be made into test paper, kits or detection chips to be applied to detection of carbapenemases and carbapenem drug-resistant bacteria, detection or distinguishing of carbapenemases is realized by determining whether fluorescence intensity or color of the fluorescent probe changes or not, and accordingly pathogenic drug-resistant bacteria with expression of carbapenemases can be detected quickly, reasonable utilization of antibiotics in treatment or clinical application can be guided, and important significance to avoidance or low consumption of antibiotics is achieved.

The invention provides an anti-IMP type carbapenemase hybridoma cell strain, a monoclonal antibody and application. The hybridoma cell strain capable of stably secreting an anti-IMP type carbapenemaseantibody and a variable region sequence of the hybridoma cell strain are obtained by screening a mouse hybridoma monoclonal antibody and cloning an Ig variable region gene by an RT-PCR method, and the antibody binding specificity is identified by an ELISA method; the obtained anti-IMP type carbapenemase antibody can be used for detecting IMP type carbapenemase, the titer reaches 1:640000 or more,and the anti-IMP type carbapenemase antibody can be prepared into an in-vitro diagnostic kit or microfluidic chip for early typing of drug-resistant strains, guiding medication and assisted clinicalinfection control and treatment, and has important significance for improving the medical and health level of China.

The invention relates to a detection chip for familiar resistant organisms and its preparation and application methods belonging to microorganism detection field. The invention employs DAN chip method including fixing the synthesized oligonucleotide probes for clinical detection of familiar resistant organisms on the slide surface to form a dot-plot, hybridizing the pending sample DNA with the chip to obtain a great deal of gene sequence information relative to the bacteria identification and drug tolerance, identifying the kinds of the familiar pathogenicbacterias existing in the clinical sample, thus to implement the identification of the clinical familiar pathogenicbacterias and detection of the main drug resistant spectrum. The invention is simple, convenient, quick, sensitive and specific, and can obviously shorten the disease diagnosis time.

The invention discloses antibacterial peptides and application of the antibacterial peptides to preparation of a medicament resisting drug-resistant bacteria. The antibacterial peptides consist of 21 amino acids, wherein the amino acid sequence is shown as SEQIDNO.1. The in-vivo and in-vitro research shows that six kinds of antibacterial peptides have a strong inhibiting and killing action for the mostly clinically-separated drug-resistant bacteria and can remarkably reduce the mortality of a septicemia model caused by the drug-resistant bacteria; and a hemolytic test and an acute local stimulus test results show that six kinds of derivates have no hemolytic test or acute toxic stimulus reaction when the concentration is 2.5mg / mL.

The invention relates to a new application of benzo [C] phenanthridine as formula I and original tropine alkaloid for preparing anti-drug-resistant bacterial drug, wherein R1-R10, R12-R15 are hydrogen and hydroxyl groups, cycloalkyl or alkyl groups with 1-12 carbon atoms, alkox or acyloxy groups, benzyloxy, chlorine or other halide atoms, amido, methylol, aldehydo, aldehydo, acetonyl, carboxy group, mesyloxy, 4-methyl-benzene sulfonyl oxygen group, aryl sulfonyl oxygen group, biphenyl phosphine acyloxy and -OCONH2, R11 is hydrogen, methyl or oxygen atom, R5 and R6 (or R15 of the formula I), R14 and R15 are formed with double bonds, R12 or R13 and nearby N atoms are formed with double bonds, N atom can be tertiary or quaternary N type, the substituents of nearby carbons of R1-R10 can have dioxolane structure. The inventive alkaloid can effectively restrain and kill drug-resistant bacterials as MRSA and ESBLs.

The present invention belongs to the field of screening antituberculotic target, vaccine antigen and detecting target in molecular biological technology, and is especially process of screening protein resisting rifampicin as antituberculotic. The process includes the first culturing drug resistant strain, the subsequent separating protein of drug resistant strain from protein of sensitive strain, comparing protein of drug resistant strain and protein of sensitive strain to determine the drug resistant protein, and final separating and identifying drug resistant protein. The process of the present invention can separate and identify drug resistant protein of Mycobacterium tuberculosis to provide new way for further understanding the drug resisting mechanism of Mycobacterium tuberculosis, fast clinical detection of drug resistant strain, and developing vaccine and medicine.

The invention discloses application of elsholtzia volatile oil in anti-bacteria and antibiotic resistant bacteria. The elsholtzia volatile oil is extracted by steam distillation. The elsholtzia volatile oil has certain functions of killing and / or inhibiting growth on bacteria of staphylococcus, escherichia coli, candida, pseudomonas, enterobacter, streptococcus and the like and fungi. The elsholtzia volatile oil has certain functions of killing and / or inhibiting growth on bacteria of drug-resistant staphylococcus, drug-resistant escherichia coli, drug-resistant enterobacter, drug-resistant klebsiella, drug-resistant pseudomonas, drug-resistant acinetobacter, drug-resistant streptococcus, and drug-resistant enterococcus and the like. The elsholtzia volatile oil can be used in industries offood, medicine, health care products, cosmetics and the like and can be used for preparing various forms of products with antibacterial and antibiotic resistant bacteria functions, and belongs to thenew application field of the elsholtzia volatile oil.

The invention provides a compound with antibacterial synergism as well as a preparation method and application thereof. The compound has stronger antibacterial synergism, can remarkably improve antibacterial effect, especially for drug-resistant strains while being combined with antibacterial drugs for use. Especially in case of being combined with macrolide antibiotics and the like for use, the compound achieves antibacterial synergism, can assist antibiotics to restrain or kill sensitive bacteria and drug-resistant bacteria, for example staphylococcus aureus which is sensitive and drug-resistant to erythromycin. By adopting the compound and a pharmaceutically acceptable carrier, a pharmaceutical composition and a medicinal preparation can be prepared and antibacterial drug synergist can also be prepared.

The invention discloses indole compounds represented by the general formula defined in the specification and salts and preparation method thereof, corresponding medical uses of the compounds and the salts thereof, and drugs and disinfectants containing the compounds and the salts thereof. A lot of experiments prove that the compounds and the salts thereof have good bacteriostatic and bactericidal activity on MRSA (drug-resistant staphylococcus aureus), MDR K.pneumonia (drug-resistant klebsiella pneumonia), and MDR A.baumanii (drug-resistant acinetobacter baumannii). In the formula, X is methylene, carbonyl or sulfonyl; R1 is fluorine, chlorine, bromine, methoxy acyl, nitro or hydrogen; R2 is methoxyl acyl, (p-methoxyl acyl)phenyl, (p-trifluoro oxy)phenyl, (p-trifluoro)phenyl, (m-methoxy acyl)phenyl, (m-trifluoro oxy)phenyl, (p-fluoro m-chloro)phenyl or hydrogen; and HA is inorganic acid or a part of organic acid with strong acidity, preferably hydrochloric acid or hydrobromic acid.

The invention relates to gopalamicin derivatives and application of the same in inhibition of infection by drug-resistant bacteria and drug-resistant mycobacterium tuberculosis. The derivatives are originated from fermentation products of marine actinomycete Streptomyces sp. 7-145. Results of experimental study show that discovered compounds with novel structures and known structures all have strong antibacterial activity on tested drug-resistant bacteria and drug-resistant mycobacterium tuberculosis and are expected to become clinically-useful novel drugs used for inhibition of infection by drug-resistant bacteria and drug-resistant mycobacterium tuberculosis.

The invention relates to ainsliaea fragrans champ caffeoylquinic acid extracts and preparation and application thereof. The ainsliaea fragrans champ caffeoylquinic acid extracts are prepared by the following steps of: performing refluxing extraction of the ainsliaea fragrans champ by using ethanol, filtering, concentrating and removing ethanol, adjusting the pH value to 1 to 3 by adding hydrochloric acid, applying macroporous adsorbent resin, water-washing, adding ethanol for gradient elution, and collecting eluent, of which the ethanol concentration is 50 to 70 percent; performing condensation and ethanol removal, adjusting the pH value to 1 to 3 by adding hydrochloric acid, using macroporous adsorbent resin, adding water and ethanol for gradient elution respectively, and collecting the eluent, of which the ethanol concentration is 40 to 70 percent; mixing the eluent, and vacuum drying the eluent to obtain the extracts. The UV content of the ainsliaea fragrans champ caffeoylquinic acid extracts is over 70 percent, the HPLC content is over 50 percent, and the content of 3-caffeoylquinic acid and the content of 3,5-dicaffeoylquinic acid are both over 10 percent. The ainsliaea fragrans champ caffeoylquinic acid extracts have the effects of resisting inflammations, bacteria, medicament-resistant strains, well improves pathologically changed tissues of rat suffering from cervicitis, obviously reduces the uterus index and the number of leukocytes and can be independently prepared into the medicaments for treating cervicitis or combined with other medicaments to prepare the medicaments for treating cervicitis.

The invention provides a salmonella broad-spectrum virulent bacteriophage. The preservation number of the bacteriophage is CCTCC NO: M 2020839. The invention also provides a preparation process and application of the salmonella broad-spectrum virulent bacteriophage, and the preparation process comprises fermentation and extraction; in the step of fermentation, a salmonella gallinarum attenuated vaccine strain is used as host bacteria for bacteriophage fermentation. The bacteriophage XPARCPS02 disclosed by the invention can be used for cracking salmonella of various serotypes and also has different degrees of cracking effects on drug-resistant bacteria; the salmonella typhimurium lysate lysate has a cracking capability on salmonella typhimurium, salmonella typhimurium drug-resistant bacteria, salmonella gallinarum, salmonella enteritidis, salmonella enteritidis drug-resistant bacteria, salmonella typhimurium, salmonella pullorum, salmonella paratyphi A, salmonella paratyphi B and salmonella dubicularis.

The invention provides a highly efficient antibacterial combination of nano silver (including nano silver, polyvinylpyrrolidone-modified nano silver and sodium citrate-modified nano silver) and kanamycin. Whether sensitive strains (escherichia coli) or drug-resistant strains (pseudomonas aeruginosa), compared with single drug administration, combined effects of a low dose of the nano silver and a low dose of the kanamycin can achieve synergistic antibacterial effect, that is to say, when the two components are combined, the concentrations of the two components are both less than 1 / 4 of the concentration of the nano silver or the kanamycin during alone acting, and a significant synergistic antibacterial effect is generated. The combined synergistic antibacterial effect of the sodium citrate-modified nano silver and the kanamycin is most significant. The combination method is simple, the cost is low, and the bactericidal effect is excellent; the antibacterial combination has good bactericidal property on the drug-resistant strains, can be applied in combined use of antibacterial agents in the medicines and agricultural production fields, and provides basic data and use guidance.

The invention discloses design of polypeptides specifically binding to immune protein of a pseudomonas aeruginosa type VI secretion system, and validation of antibacterial activity of the polypeptides. The invention first protects a polypeptide, and the polypeptide is shown by a sequence 3 or a sequence 4 in a sequence table. The gene encoding of the polypeptides also falls within the scope of protection of the invention. The invention also protects the application of the polypeptides: binding to the immune protein in the bacteria type VI secretion system; enriching the immune protein in the bacteria type VI secretion system; detecting the immune protein in the bacteria type VI secretion system. The functional short peptides provided by the invention can bond to the immune protein togetherwith effector protein in a competitive way, so that the interaction between TplE and TplEi is destroyed, and the effector protein is further enabled to break down the cell membranes of bacteria and cause the bacteria to die; therefore, the design is a most potent novel antibacterial strategy taking the T6SS effector protein as a target, and a new direction is provided for the treatment of clinically drug-resistant strains.

The invention discloses a preparation method for a dichloro substituted II-type halogenated polyketone compound zunyimycin A, wherein the compound is derived from a secondary metabolite of a streptomyces sp.FJS31-2 strain (with the strain preservation number of CGMCC4.7321), and finally, a structure is identified and determined after strain activation, expansion culture and isolation. The compoundcan be used in treatment of diseases infected by gram-positive bacteria such as staphylococcus aureus (MRSA) and drug-resistant bacteria thereof, staphylococcus epidermidis, bacillus subtilis and thelike, is used in treatment of diseases infected by gram-negative bacteria such as super-spectrum beta-lactamase escherichia coli (ESBL), proteusbacillus vulgaris, bacterium burgeri and the like, andis used for treatment of diseases infected by fungi, such as candida albicans.

The invention discloses application of dihydroquercetin and glucoside compounds to preparing a medicine for resisting drug-fast bacteria. With the invention, the dihydroquercetin and glucoside compounds can be extracted from decogenus plants, such as hypericum japonicum Thunb, and the activity of the dihydroquercetin and glucoside compounds for resisting the drug-fast bacteria can be proved; proved by a pharmacological experiment, the dihydroquercetin and glucoside compounds not only have remarkable direct inhibition function on common-clinically meticillin-resistant staphylococcus aureus (MRSA), but also can enhance the action of the traditional antibiotic for resisting the drug-fast bacteria. The dihydroquercetin and glucoside compounds can be further used as active components and used for preparing a medicine for treating the drug-fast bacteria infection; and preparation forms includes oral preparations, injections and / or external preparations which are prepared by combining with acceptable carriers.

The invention provides a medicine composition taking medicines which benefit qi and activate blood circulation and clear away heat and toxic materials for compatibility. The medicine composition has exact treatment effects on various inflammations caused by standard bacteria strains and medicine resistant strains (such as KPC positive or superbacteria NDM-1 positive) such as respiratory tract infection, pelvic cavity infection, urinary infection and acute peritonitis. The medicine composition is a combined preparation of one or more of radix astragali, ginseng, American ginseng, dangshen, heterophylly falsestarwort root, largehead atractylodes rhizome, liquorice and Chinese yam, one or more of salvia miltiorrhiza, red peony root, leeches, Sichuan lovage rhizome, safflower, peach kernels, pseudo-ginseng, rosewood, rhizoma corydalis, ground beetle, motherwort herb, Chinese angelica and giant knotweed rhizome and one or more of honeysuckle, weeping forsythia capsule, isatis root, dyers woad leaf, dandelion, baical skullcap root, heartleaf houttuynia herb, dahurian patrinia herb, common andrographis herb, Tokyo violet herb, herba corydalis bungeanae, gueldenstaedtia multiflora bunge, globeflower and wild chrysanthemum in clinically reasonable doses.